Italy looks at medicine price cuts while Spain moves on discounts
This article was originally published in Scrip
The Italian government is likely to introduce medicine price cuts in a bid to save €2 billion on drug spending. Meanwhile, the Spanish cabinet recently approved a bill that will see discounts applied to state-financed patented medicines, and France is to bring forward a range of pricecuts that among other things could affect Merck & Co's antihypertensive Cozaar (losartan).
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.